1.Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors (Posted: 11/03/2009) - In this clinical trial, patients who have solid tumors that cannot be removed by surgery or that have spread to other areas of the body will be treated with the PARP inhibitor AZD2281 and chemotherapy drugs cisplatin and gemcitabine. 2.Comparing Second-Line Therapies for Advanced Lung Cancer (Posted: 07/28/2009) - In this trial, patients with advanced non-small cell lung cancer that has recurred or progressed after initial chemotherapy will be tested for EGFR gene amplification and then randomly assigned to receive either pemetrexed or erlotinib. 3.Comparing Surgical Treatment for Small NSCLC Tumors (Posted: 11/04/2008) - In this randomized phase III trial, patients with stage 1A non-small cell lung cancer tumors measuring 2 centimeters or less and located in the outer third of the lung are randomly assigned to sublobar resection (either wedge resection or segmentectomy) or lobectomy. 4.Pilot Study of Erlotinib to Treat NSCLC (Posted: 06/07/2005, Updated: 10/01/2007) - In this study, researchers hope to identify tumor characteristics associated with responses to treatment with the drug erlotinib that may be predictors of a survival advantage. The study will also test erlotinib as a first-line therapy for advanced NSCLC. 5.Adjuvant Treatment for Resected Lung Cancer (Posted: 08/07/2007) - In this clinical trial, doctors are exploring whether the addition of bevacizumab to adjuvant chemotherapy can help patients with early non-small cell lung cancer (NSCLC) live longer following surgery to remove their tumors.
